XML 43 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Finite Lived Intangible Assets [Line Items]        
Amortization expense $ 425,108 $ 425,107 $ 850,215 $ 850,214
Amortization of license agreements remainder of fiscal year 2019 850,214   850,214  
Amortization of license agreements in 2020 1,700,429   1,700,429  
Amortization of license agreements in 2021 1,700,429   1,700,429  
Amortization of license agreements in 2022 1,700,429   1,700,429  
Amortization of license agreements in 2023 1,700,429   1,700,429  
Amortization of license agreements, thereafter 10,261,865   $ 10,261,865  
Novartis | Licensing Agreement        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     21 years  
Finite-lived intangible assets, accumulated amortization 605,988   $ 605,988  
Novartis | Patents        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     14 years  
Finite-lived intangible assets, accumulated amortization $ 6,337,431   $ 6,337,431